# Neoadjuvant Chemotherapy With a Combination of Pegylated Liposomal Doxorubicin (Caelyx®) and Paclitaxel in Breast Cancer

> **NCT03221881** · NA · COMPLETED · sponsor: **Hebei Medical University Fourth Hospital** · enrollment: 100 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Pegylated Liposomal Doxorubicin and docetaxel

## Key facts

- **NCT ID:** NCT03221881
- **Lead sponsor:** Hebei Medical University Fourth Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2017-04
- **Final completion:** 2017-06
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2017-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03221881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03221881, "Neoadjuvant Chemotherapy With a Combination of Pegylated Liposomal Doxorubicin (Caelyx®) and Paclitaxel in Breast Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03221881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*